Aspen expects HEPS down between 19% and 24%, to between 602.0c and 641.6c. Revenue was broadly flat, while Commercial Pharmaceuticals delivered mid single digit growth. Normalised EBITDA rose between 7% and 12%, supported by efficiency gains and Commercial Pharmaceuticals. Restructuring costs of R2.3bn weighed on HEPS, while APAC generated R28bn proceeds. Results are due 2 September 2026.
Click here to read the SENS